CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Ingestible (vibrating) capsule devices for chronic constipation — Coverage Criteria

This policy governs coverage and coding for ingestible (vibrating) capsule devices marketed to mechanically stimulate the colon for treatment of chronic constipation, and applies to Medicare Advantage and Commercial products administered by Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIngestible (vibrating) capsule devices for chronic constipation — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateOct 1, 2023

Next Review DateNov 20, 2024

Key ActionDo not submit prior authorization; prior authorization is not applicable per this policy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

A9268,A9269HCPCS codes listed as not covered / not medically necessary

Aug 26, 2022Vibrant Gastro System de novo clearance date

8-15%Estimated prevalence of constipation

Insufficient evidencePolicy stance on clinical benefit

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General coverage determination

Covered when ALL of the following are met:

Policy coverage determination: Ingestible devices (vibrating capsules) for treatment of constipation are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products because the evidence is insufficient to determine effects on health outcomes.

policy-level stance

For Medicare Advantage members, ingestible vibrating capsule systems and their associated programmers (HCPCS A9268 and A9269) are excluded and considered not covered. This policy-level exclusion reflects the determination that available evidence is insufficient to establish clinical benefit for these technologies in the treatment of constipation.

For Commercial products administered by Blue Cross Blue Shield - Rhode Island, ingestible vibrating capsules for the treatment of constipation are considered not medically necessary due to insufficient evidence to determine effects on health outcomes.

What Providers Need to Know

Prior Authorization

Prior Authorization: Not applicable. No prior authorization is required for ingestible devices per this policy.

Step Therapy

Clinical step prior to device (FDA label)

Per FDA labeling for the Vibrant Gastro System, a trial of laxative therapy must have failed prior to device use. Specifically, the device is indicated for adults with chronic idiopathic constipation after failure of at least a 1-month trial of laxative therapy.

Documentation Required

Benefit verification and documentation

Benefit verification is the provider's responsibility. Confirm member benefits, coverage, and any contract-specific limitations or exclusions by checking the member's Benefit Booklet / Evidence of Coverage / Subscriber Agreement before ordering or providing services. Coverage may vary by group/contract.

Refer to the member's specific Benefit Booklet / Evidence of Coverage / Subscriber Agreement
Contact the payer/provider call center for member-specific eligibility and benefits

Denial Risk

Coverage denial triggers

Coverage and medical necessity limits: ingestible devices for treatment of constipation are considered not covered for Medicare Advantage plans and not medically necessary for Commercial products based on insufficient evidence. Providers should anticipate coverage denials in these cases and document medical necessity thoroughly if pursuing payment. The following HCPCS codes are identified as not covered / not medically necessary: A9268, A9269.

Not covered for Medicare Advantage and not medically necessary for Commercial products per policy
HCPCS: A9268, A9269 (not covered, effective 10/01/2023)
If services are rendered that are non-covered or not medically necessary, obtain written agreement from the member before billing the member directly

Background and Epidemiology

Constipation affects an estimated 8–15% of the population and is more common in women, older adults, racial/ethnic minority groups, and individuals of lower socioeconomic status. Primary constipation is defined by symptom-based criteria (Rome IV) and initial management typically includes lifestyle modification and laxatives; more refractory cases may require pharmacologic therapies, biofeedback, or surgical interventions. The Vibrant Gastro System is an example of an ingestible vibrating capsule cleared by the FDA for adults with chronic idiopathic constipation after failure of at least a one-month trial of laxatives; it is proposed to mechanically stimulate the colon and resynchronize circadian bowel rhythms, but clinical benefit remains uncertain.

Key Definitions

Complete Spontaneous Bowel Movement (CSBM) — definition and trial outcome measure

DefinitionComplete Spontaneous Bowel Movement (CSBM): A bowel movement occurring without use of rescue laxatives.

Outcome measure in trialsCSBM is used as a trial outcome measure; studies defined response as an increase of ≥1 CSBM per week.

Context of useUsed to quantify efficacy of treatments for chronic idiopathic or functional constipation in clinical studies.

Functional constipation / Rome IV criteria — diagnostic criteria summary

Core diagnostic featuresFunctional constipation is defined by symptoms including fewer than 3 stools per week, straining at stool, sensation of incomplete evacuation, and need for digital assistance.

Rome IV symptom thresholdDiagnosis requires at least two or more of the listed symptoms affecting >25% of bowel movements for at least 6 months, with active symptoms in the past 3 months.

Related categoriesPrimary constipation may be categorized as functional constipation, constipation‑predominant IBS, or defecatory disorders.